Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selec...

詳細記述

保存先:
書誌詳細
主要な著者: Flaherty, Keith T., Infante, Jeffery R., Daud, Adil, Gonzalez, Rene, Kefford, Richard F., Sosman, Jeffrey, Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Ibrahim, Nageatte, Kudchadkar, Ragini, Burris, Howard A., Falchook, Gerald, Algazi, Alain, Lewis, Karl, Long, Georgina V., Puzanov, Igor, Lebowitz, Peter, Singh, Ajay, Little, Shonda, Sun, Peng, Allred, Alicia, Ouellet, Daniele, Kim, Kevin B., Patel, Kiran, Weber, Jeffrey
フォーマット: Artigo
言語:Inglês
出版事項: 2012
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3549295/
https://ncbi.nlm.nih.gov/pubmed/23020132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1210093
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料